With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...

On Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted third-quarter revenues of $11.89 billion, beating the consensus of ...

Sales of blood cancer drug Revlimid, which is now facing generic competition, dropped 11% to $1.41 billion in the quarter, ...

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

The pharmaceutical company posted third-quarter adjusted earnings a share of $1.80 on revenue of $11.9 billion.

Squibb “announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the ...

Analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), boosting the price target ...

Bristol Myers Squibb (BMY) is set to announce Q3 earnings. Analysts expect profit of $1.50 per share on revenue of $11.25B.

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology ...

On September 29, BMO Capital raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) from $48 to $53, maintaining ...